期刊
VACCINE
卷 23, 期 15, 页码 1828-1832出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2004.11.013
关键词
algae; Chlamydomonas reinhardtii; IgA; human monoclonal antibodies; single chain antibodies
资金
- NIAID NIH HHS [R01 AI059614-02, R01 AI059614] Funding Source: Medline
- NIGMS NIH HHS [R01GM54659] Funding Source: Medline
Protein based therapeutics have enjoyed great success over the past decade. Unfortunately, with this clinical success comes a heavy price tag, owing to the inherently high costs of capitalization and production using mammalian cell fermentation. To address this problem, we have begun developing a system for the expression of recombinant proteins in the unicellular eukaryotic green algae, Chlamydomonas reinhardtii, leading to the production of human IgA single chain antibodies. The expression of human monoclonal antibodies in C. reinhardtii offers an attractive alternative to traditional mammalian based expression systems for several reasons, including an ability to rapidly obtain stable plastid and nuclear transformants, coupled with inherently low costs of capitalization and production. (c) 2004 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据